AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17879663 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate nostril yoga breathing
Number of subjects: 20
Study 17879663 — intervention group
Group type: EXPERIMENTAL
Intervention: Left nostril yoga breathing
Number of subjects: 20
Study 17879663 — intervention group
Group type: COMPARATOR
Intervention: Breath awareness (control)
Number of subjects: 20
Study 15486923 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE-covered stents
Number of subjects: 25
Study 15486923 — intervention group
Group type: COMPARATOR
Intervention: Bare stents
Number of subjects: 25
Study 16519421 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified motor cortex stimulation (MCS)
Number of subjects: 15
Study 16519421 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological testing (phentolamine, lidocaine, ketamine, thiopental, morphine, placebo)
Number of subjects: 15
Study 9848030 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 227
Study 9848030 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 227
Study 7848901 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggulipid (50 mg capsules twice daily for 24 weeks)
Number of subjects: 61
Study 7848901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (capsules twice daily for 24 weeks)
Number of subjects: 61
Study 7848901 — intervention group
Group type: EXPERIMENTAL
Intervention: Guggulipid (after 12-week washout)
Number of subjects: 61
Study 7848901 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after 12-week washout)
Number of subjects: 61
Study 2903480 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant (Curosurf) 200 mg/kg
Number of subjects: 146
Study 4513355 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent combination chemotherapy as the only form of maintenance
Number of subjects: 72
Study 4513355 — intervention group
Group type: COMPARATOR
Intervention: Weekly immunotherapy in addition to chemotherapy
Number of subjects: 72
Study 27909712 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial perfusion SPECT (MPS) using Tc‐99m radiopharmaceuticals
Number of subjects: 121939
Study 27909712 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological stress tests (adenosine, regadenoson, dipyridamole, dobutamine)
Number of subjects: 121939
Study 27909712 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPECT
Number of subjects: 121939
Study 27909712 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS scoring by default
Number of subjects: 121939
Study 27909712 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in MPS count
Number of subjects: 121939
Study 27909712 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests for MPS
Number of subjects: 121939
Study 26365443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of PTQXT
Number of subjects: 275
Study 26365443 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of PTQXT combined with external application of Chinese herbs
Number of subjects: 275
Study 26365443 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral antihistamine and placebo PTQXT pills with topical 1% mometasone furoate)
Number of subjects: 275
Study 26365443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Chinese herbal medicine-treated groups
Number of subjects: 275
Study 23311981 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse telephone follow-up on postoperative days 1, 3, 5, and 10
Number of subjects: 45
Study 23311981 — intervention group
Group type: COMPARATOR
Intervention: Standard care with no follow-up
Number of subjects: 45
Study 22289539 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 2 mg/kg intravenous bolus plus normal saline by intravenous infusion (K group, n = 30)
Number of subjects: 60
Study 22289539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg/kg intravenous bolus plus remifentanil 0.15 μg/kg per min intravenous infusion (KR group, n = 30)
Number of subjects: 60
Study 19491658 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ATP (8‐10 h/week, maximum 50 microg/kg/min) for 8 weeks
Number of subjects: 99
Study 19491658 — intervention group
Group type: COMPARATOR
Intervention: No ATP (control group)
Number of subjects: 99
Study 16941969 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-inflammatory analgesic medicine combined with acupuncture at Tiaokou (ST 38)
Number of subjects: 257
Study 16941969 — intervention group
Group type: COMPARATOR
Intervention: Oral anti-inflammatory analgesic medicine
Number of subjects: 257
Study 12694150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 micro g kg‐1
Number of subjects: 40
Study 12694150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10731509 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium mineral water (344 mg Ca/L)
Number of subjects: 12
Study 10731509 — intervention group
Group type: COMPARATOR
Intervention: Low-calcium mineral water (<10 mg/L)
Number of subjects: 12
Study 9163027 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir (treatment of choice for HSE)
Number of subjects: 0
Study 1568701 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y anastomosis
Number of subjects: 22
Study 1568701 — intervention group
Group type: COMPARATOR
Intervention: Billroth II anastomosis
Number of subjects: 22
Study 1568701 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y and Billroth II anastomosis
Number of subjects: 22
Study 6146156 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 17
Study 6146156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31461079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led multicomponent intervention
Number of subjects: 46
Study 30596746 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial SMS (N = 195)
Number of subjects: 388
Study 30596746 — intervention group
Group type: COMPARATOR
Intervention: Trial Control (N = 193)
Number of subjects: 388
Study 30596746 — intervention group
Group type: COMPARATOR
Intervention: Comparison Cohort (N = 727)
Number of subjects: 388
Study 27372434 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine pre-administration (1% lidocaine 30mg)
Number of subjects: 96
Study 27372434 — intervention group
Group type: EXPERIMENTAL
Intervention: Local warming (43°C forced air for 1min)
Number of subjects: 96
Study 27372434 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 24875302 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome sequencing information
Number of subjects: 39
Study 22689677 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus/tacrolimus
Number of subjects: 74
Study 22689677 — intervention group
Group type: COMPARATOR
Intervention: methotrexate/tacrolimus
Number of subjects: 74
Study 20653641 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg daily for 3 days
Number of subjects: 11
Study 20653641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18983270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oportunidades conditional cash transfer programme
Number of subjects: 840
Study 11236121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose systemic methotrexate (50 mg/m2)
Number of subjects: 62
Study 11236121 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic surgery
Number of subjects: 62
Study 10211031 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% liposome-encapsulated tetracaine (LET)
Number of subjects: 40
Study 10211031 — intervention group
Group type: COMPARATOR
Intervention: 5% eutectic mixture of local anaesthetics (EMLA)
Number of subjects: 40
Study 10211031 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anaesthetic effect
Number of subjects: 40
Study 7877746 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated patients with Parkinson's disease
Number of subjects: 0
Study 7877746 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy controls
Number of subjects: 0
Study 3357154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent 'low-friction' self-catheterization
Number of subjects: 42
Study 3357154 — intervention group
Group type: COMPARATOR
Intervention: Urethrotomy
Number of subjects: 42
Study 31593081 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent therapy (MT group) consisting of health education, exercise, and cognitive-behavioral therapy during 12 weeks in 2-hourly weekly sessions.
Number of subjects: 336
Study 31593081 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care (control group).
Number of subjects: 336
Study 28291838 — intervention group
Group type: EXPERIMENTAL
Intervention: Theoretical and practical exercise counseling
Number of subjects: 300
Study 28291838 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study 26116999 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE)
Number of subjects: 19
Study 26116999 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MIE)
Number of subjects: 19
Study 26116999 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 19
Study 23076726 — intervention group
Group type: EXPERIMENTAL
Intervention: Building-only intervention
Number of subjects: 2500
Study 23076726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 2500
Study 23076726 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom intervention
Number of subjects: 2500
Study 21569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg on Day 1
Number of subjects: 652
Study 21569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 156 mg on Day 8
Number of subjects: 652
Study 21569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg (Days 1 to 7)
Number of subjects: 652
Study 21569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 156 mg (Days 8 to 36)
Number of subjects: 652
Study 21569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 39 mg (Days 8 to 36)
Number of subjects: 652
Study 21569242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 234 mg (Days 8 to 36)
Number of subjects: 652
Study 21569242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 19355800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 4 mg once daily
Number of subjects: 0
Study 19355800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily
Number of subjects: 0
Study 19355800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16573577 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol plus energy drink (vodka 37.5% v/v and Red Bull 3.57 mL/kg)
Number of subjects: 26
Study 16573577 — intervention group
Group type: COMPARATOR
Intervention: Energy drink alone
Number of subjects: 26
Study 16573577 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 26
Study 12771499 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic Restorative Treatment (ART) with glass-ionomer
Number of subjects: 152
Study 12771499 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional approach with amalgam
Number of subjects: 152
Study 12771499 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-conventional approach with amalgam
Number of subjects: 152
Study 12771499 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional approach with glass-ionomer
Number of subjects: 152
Study 12771499 — intervention group
Group type: EXPERIMENTAL
Intervention: All occlusal amalgam restorations
Number of subjects: 152
Study 12771499 — intervention group
Group type: EXPERIMENTAL
Intervention: All glass-ionomer restorations
Number of subjects: 152
Study 12771499 — intervention group
Group type: COMPARATOR
Intervention: Comparison of secondary caries
Number of subjects: 152
Study 10702774 — intervention group
Group type: EXPERIMENTAL
Intervention: Group meetings
Number of subjects: 102
Study 10702774 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondence course
Number of subjects: 102
Study 10702774 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 102
Study 9179367 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscum album agglutinin-I (10 and 1 ng/ml)
Number of subjects: 0
Study 9179367 — intervention group
Group type: COMPARATOR
Intervention: Viscum album agglutinin-I (lectin-enriched preparation)
Number of subjects: 0
Study 9179367 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly isolated Viscum album agglutinin-I
Number of subjects: 0
Study 8409723 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy
Number of subjects: 1036
Study 8409723 — intervention group
Group type: COMPARATOR
Intervention: Ligatures
Number of subjects: 1036
Study 29708650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 737
Study 29708650 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 737
Study 29708650 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 737
Study 29096614 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially-enhanced experimental condition (pedometer plus app with social and gamification features)
Number of subjects: 440
Study 29096614 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic experimental condition (pedometer plus basic app with no social and gamification features)
Number of subjects: 440
Study 29096614 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 440
Study 26501386 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg intraoperative methylprednisolone
Number of subjects: 1043
Study 26501386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1043
Study 23107996 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent information exposure
Number of subjects: 20
Study 23107996 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent information exposure
Number of subjects: 20
Study 20929999 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (CGM) for 4 weeks
Number of subjects: 0
Study 20929999 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for 4 weeks
Number of subjects: 0
Study 18386049 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise countermeasure (RVE)
Number of subjects: 16
Study 18386049 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (Ctrl)
Number of subjects: 16
Study 16871570 — intervention group
Group type: EXPERIMENTAL
Intervention: TMA Assay (LOD 9.6 IU/mL)
Number of subjects: 1145
Study 16871570 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative TMA results
Number of subjects: 1145
Study 16871570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single positive TMA test
Number of subjects: 1145
Study 12759295 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, subcutaneously, twice weekly)
Number of subjects: 20
Study 12759295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11120531 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate infusion therapy (100 mg/m² intravenous bolus followed by 200 mg/m² infusion)
Number of subjects: 59
Study 11120531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate, etoposide, and bleomycin)
Number of subjects: 59
Study 11120531 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 59
Study 9256623 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% isopropyl unoprostone
Number of subjects: 9
Study 9256623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1.5 mg per day
Number of subjects: 274
Study 8211872 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 1.5 mg per day
Number of subjects: 274
Study 3102372 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (4g/day)
Number of subjects: 0
Study 3102372 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2g/day)
Number of subjects: 0
Study 3102372 — intervention group
Group type: COMPARATOR
Intervention: Control group (no L-carnitine)
Number of subjects: 0
Study 30975570 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV/dPly/PhtD (10 or 30 µg of each protein) with 3+0 schedule (2‐3‐4 months)
Number of subjects: 1200
Study 30975570 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV/dPly/PhtD (30 µg of each protein) with 2+1 schedule (2‐4‐9 months)
Number of subjects: 1200
Study 30975570 — intervention group
Group type: EXPERIMENTAL
Intervention: PHiD‐CV
Number of subjects: 1200
Study 30975570 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw‐HBV/Hib, OPV, measles, yellow fever vaccines co-administered with pneumococcal proteins
Number of subjects: 1200
Study 30975570 — intervention group
Group type: COMPARATOR
Intervention: Co-administered vaccines
Number of subjects: 1200
Study 29627709 — intervention group
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF
Number of subjects: 1733
Study 29627709 — intervention group
Group type: COMPARATOR
Intervention: E/C/F/TDF
Number of subjects: 1733
Study 26649812 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused Enhanced Cognitive Behavior Therapy (CBT‐Ef)
Number of subjects: 50
Study 26649812 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad Enhanced Cognitive Behavior Therapy (CBT‐Eb)
Number of subjects: 50
Study 26649812 — intervention group
Group type: COMPARATOR
Intervention: Both CBT‐Ef and CBT‐Eb
Number of subjects: 50
Study 25319689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral contraction of homonymous (elbow flexor) muscles
Number of subjects: 0
Study 25319689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral contraction of heteronymous (elbow flexor and extensor) muscles
Number of subjects: 0
Study 25319689 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial rotation of the head
Number of subjects: 0
Study 25319689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral rotation of the head
Number of subjects: 0
Study 25319689 — intervention group
Group type: EXPERIMENTAL
Intervention: Head flexion and extension
Number of subjects: 0
Study 22678326 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic colectomy (HALC)
Number of subjects: 116
Study 22678326 — intervention group
Group type: COMPARATOR
Intervention: Open colectomy (OC)
Number of subjects: 116
Study 20297882 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive-supportive counseling groups (experimental group)
Number of subjects: 164
Study 20297882 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (control group)
Number of subjects: 164
Study 17568955 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent-comprehensive assessment
Number of subjects: 235
Study 17568955 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent-brief assessment
Number of subjects: 235
Study 17568955 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent-comprehensive assessment
Number of subjects: 235
Study 17568955 — intervention group
Group type: COMPARATOR
Intervention: Infrequent-brief assessment
Number of subjects: 235
Study 16151286 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot fascia iliaca compartment block (FICB) with ropivacaine 0.2% for bolus and saline for infusion
Number of subjects: 81
Study 16151286 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (FICB) with ropivacaine 0.2% for bolus and infusion
Number of subjects: 81
Study 16151286 — intervention group
Group type: COMPARATOR
Intervention: Control group with saline for both bolus and infusion
Number of subjects: 81
Study 14753247 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-134a
Number of subjects: 270
Study 14753247 — intervention group
Group type: COMPARATOR
Intervention: CFC
Number of subjects: 270
Study 10533689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam administration
Number of subjects: 20
Study 10533689 — intervention group
Group type: COMPARATOR
Intervention: Teaching at 3 hours after midazolam administration
Number of subjects: 20
Study 9084546 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.06 mg/kg) and Propofol (20 mg/5 s) for induction; Propofol (8 mg/kg/hr) for maintenance
Number of subjects: 42
Study 9084546 — intervention group
Group type: COMPARATOR
Intervention: Propofol (20 mg/5 s) for induction; Propofol (10 mg/kg/h) for maintenance
Number of subjects: 42
Study 1875206 — intervention group
Group type: COMPARATOR
Intervention: Continuous Passive Motion (CPM)
Number of subjects: 100
Study 1875206 — intervention group
Group type: COMPARATOR
Intervention: CPM with Continuous Cooling Pad (CCP)
Number of subjects: 100
Study 1875206 — intervention group
Group type: COMPARATOR
Intervention: CPM with Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 100
Study 6979255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aroused condition
Number of subjects: 24
Study 6979255 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxed condition
Number of subjects: 24
Study 6979255 — intervention group
Group type: COMPARATOR
Intervention: Alert condition
Number of subjects: 24
Study 30767407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-test counselling for BRCA testing
Number of subjects: 935
Study 28936963 — intervention group
Group type: EXPERIMENTAL
Intervention: Self made guidance for difficult gastric tube placement
Number of subjects: 40
Study 28936963 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional gastric tube placement)
Number of subjects: 40
Study 29182119 — intervention group
Group type: EXPERIMENTAL
Intervention: Poking reduction and cannulated screws fixation (Group A, N=28)
Number of subjects: 50
Study 29182119 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation using a sinus tarsi approach (Group B, N=22)
Number of subjects: 50
Study 24949907 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session computer-assisted anxiety sensitivity intervention
Number of subjects: 104
Study 24949907 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 104
Study 22629353 — intervention group
Group type: EXPERIMENTAL
Intervention: Fones technique
Number of subjects: 56